Merck, Kelun buoyed by phase 3 results for breast cancer antibody drug conjugate
JHVEPhoto/iStock Editorial via Getty Images Merc (New York Stock Exchange: Merck) and its Sichuan partner Kelun-Biotech reported that phase III data on its antibody drug candidate Sacituzumab tirumotecan (sac-TMT) led to a 69%…